Mouse models of polyglutamine diseases in therapeutic approaches: Review and data table. Part II

Molecular Neurobiology

Volumn 46, Issue 2, 2012, Pages 430-466

  Switonski, Pawel M ^a   Szlachcic, Wojciech J ^a   Gabka, Agnieszka ^a   Krzyzosiak, Wlodzimierz J ^a   Figiel, MacIej ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

DRPLA; Huntingtondisease; Mouse models; Polyglutamine; SBMA; Spinocerebellarataxia; Therapy

Indexed keywords

ANDROGEN RECEPTOR; ATAXIN 3; ATAXIN 7; BENZOTHIAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CONGO RED; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEAT SHOCK PROTEIN 70; HUNTINGTIN; KYNURENINE; METHAZOLAMIDE; MINOCYCLINE; MITHRAMYCIN; MONOMER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; NEURTURIN; OLIGOMER; POLYGLUTAMINE; PROTEASOME; RILMENIDINE; TRANSCRIPTION FACTOR; TREHALOSE; UBIQUITIN; VASCULOTROPIN;

APOPTOSIS; AUTOPHAGY; BRAIN ATROPHY; BRAIN REGION; BRAIN WEIGHT; CELL FUNCTION; CELL LOSS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFICACY; ENVIRONMENTAL ENRICHMENT; EXCITOTOXICITY; GENE SILENCING; GENETIC DISORDER; GRIP STRENGTH; HUNTINGTON CHOREA; LEARNING DISORDER; MITOCHONDRIAL PERMEABILITY; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SLEEP WAKING CYCLE;

EID: 84868093925     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8316-3     Document Type: Review

References (397)

1. Durr A (2010) Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 9(9):885-894
2. Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83-98
3. Beal MF, Ferrante RJ (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 5 (5):373-384 (Pubitemid 38568498)
4. Wagner L, Menalled L, Gomeniouk A, Brunner D, Leavitt B (2008) Huntington Disease. Animal and Translational Models for CNS Drug Discovery. Elsevier, pp 207-266
5. Bauer PO, Nukina N (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 110(6):1737-1765
6. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90(3):905-981
7. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30:575-621 (Pubitemid 47218768)
8. Shao J, Diamond MI (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 16 Spec No. 2:R115-123
9. Nedelsky NB, Todd PK, Taylor JP (2008) Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim Biophys Acta 1782(12):691-699
10. Bennett EJ, Shaler TA, Woodman B, Ryu K-Y, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR (2007) Global changes to the ubiquitin system in Huntington's disease. Nature 448(7154):704-708 (Pubitemid 47236860)
11. Martinez-Vicente M, Talloczy Z, Wong E et al (2010) Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 13(5):567-576
12. Heng MY, Duong DK, Albin RL, Tallaksen-Greene SJ, Hunter JM, Lesort MJ, Osmand A, Paulson HL, Detloff PJ (2010) Early autophagic response in a novel knock-in model of Huntington disease. Hum Mol Genet 19(19):3702-3720
13. Ortega Z, Díaz-Hernández M, Maynard CJ, Hernández F, Dantuma NP, Lucas JJ (2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci 30(10):3675-3688
14. Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443(7113):780-786 (Pubitemid 44622682)
15. Wong E, Cuervo AM (2010) Integration of clearance mechanisms: the proteasome and autophagy. Cold Spring Harb Perspect Biol 2(12):a006734
16. Ravikumar B, Vacher C, Berger Z et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6):585-595 (Pubitemid 38715985)
17. Menzies FM, Huebener J, RennaM, Bonin M, RiessO, Rubinsztein DC (2010) Autophagy induction reducesmutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 133(Pt 1):93-104
18. Fox JH, Connor T, Chopra V et al (2010) The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol Neurodegener 5:26
19. Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, Sadiq O, Brown SD, Rubinsztein DC (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet 19(11):2144-2153
20. Torashima T, Koyama C, Iizuka A, Mitsumura K, Takayama K, Yanagi S, Oue M, Yamaguchi H, Hirai H (2008) Lentivectormediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep 9(4):393-399
21. Adachi H, Waza M, Tokui K, Katsuno M, Minamiyama M, Tanaka F, Doyu M, Sobue G (2007) CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci 27(19):5115-5126 (Pubitemid 46741791)
22. Wong HK, Bauer PO, Kurosawa M et al (2008) Blocking acidsensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum Mol Genet 17(20):3223-3235
23. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101(1):57-66
24. Takahashi T, Katada S, Onodera O (2010) Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? J Mol Cell Biol 2(4):180-191
25. Nagai Y, Popiel HA (2008) Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis. Curr Pharm Des 14(30):3267-3279
26. Sánchez I, Mahlke C, Yuan J (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421(6921):373-379 (Pubitemid 36157935)
27. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PAS, Bates GP, Hockly E (2003) Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54(2):186-196 (Pubitemid 36909617)
28. Schilling G, Savonenko AV, Coonfield ML et al (2004) Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 187(1):137-149 (Pubitemid 38470019)
29. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10(2):148-154 (Pubitemid 38524884)
30. Hockly E, Tse J, Barker AL et al (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol Dis 21(1):228-236 (Pubitemid 41817321)
31. Wood NI, Pallier PN, Wanderer J, Morton AJ (2007) Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. Neurobiol Dis 25(2):342-353 (Pubitemid 46124014)
32. Chopra V, Fox JH, Lieberman G, Dorsey K, MatsonW,Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S (2007) A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A 104(42):16685-16689 (Pubitemid 350211077)
33. Yang C-R, Yu RK (2009) Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington's disease. J Neurosci Res 87(1):26-33
34. Popiel HA, Nagai Y, Fujikake N, Toda T (2009) Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci Lett 449(2):87-92
35. Wang C-E, Zhou H, McGuire JR, Cerullo V, Lee B, Li S-H, Li X-J (2008) Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 181(5):803-816 (Pubitemid 351786985)
36. Southwell AL, Ko J, Patterson PH (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 29 (43):13589-13602
37. Snyder-Keller A, McLear JA, Hathorn T, Messer A (2010) Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol 69(10):1078-1085
38. Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, Rubinsztein DC (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc Natl Acad Sci U S A 97 (17):9701-9705 (Pubitemid 30650839)
39. Novoselova TV, Margulis BA, Novoselov SS, Sapozhnikov AM, van der Spuy J, Cheetham ME, Guzhova IV (2005) Treatment with extracellular HSP70/HSC70 protein can reduce polyglutamine toxicity and aggregation. J Neurochem 94(3):597-606 (Pubitemid 41098492)
40. McLear JA, Lebrecht D, Messer A, Wolfgang WJ (2008) Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. FASEB J 22(6):2003-2011 (Pubitemid 351811476)
41. Hansson O, Nylandsted J, Castilho RF, Leist M, Jäättelä M, Brundin P (2003) Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Res 970(1-2):47-57 (Pubitemid 36423181)
42. Vacher C, Garcia-Oroz L, Rubinsztein DC (2005) Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease.Hum Mol Genet 14(22):3425-3433 (Pubitemid 41672126)
43. Orr AL, Huang S, Roberts MA, Reed JC, Li S, Li X-J (2008) Sexdependent effect of BAG1 in ameliorating motor deficits ofHuntington disease transgenic mice. J Biol Chem 283(23):16027-16036
44. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13(13):1389-1405 (Pubitemid 38961645)
45. Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S, Nakai A (2005) Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem 280(41):34908-34916 (Pubitemid 41504625)
46. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Zoghbi HY (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10(14):1511-1518 (Pubitemid 32684893)
47. Adachi H, Katsuno M, Minamiyama M et al (2003) Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 23(6):2203-2211 (Pubitemid 36368908)
48. Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F, Doyu M, Sobue G (2005) Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A 102(46):16801-16806 (Pubitemid 41688857)
49. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11(10):1088-1095 (Pubitemid 41486831)
50. Tokui K, Adachi H, Waza M et al (2009) 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 18(5):898-910
51. Jensen NM, Dalsgaard T, Jakobsen M, Nielsen RR, Sørensen CB, Bolund L, Jensen TG (2011) An update on targeted gene repair in mammalian cells: methods and mechanisms. J Biomed Sci 18:10
52. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10(8):816-820 (Pubitemid 39070854)
53. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102(16):5820-5825 (Pubitemid 40559643)
54. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ (2005) Intrastriatal rAAV-mediated delivery of antihuntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12(4):618-633 (Pubitemid 41350143)
55. Wang Y-L, Liu W, Wada E, Murata M, Wada K, Kanazawa I (2005) Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 53(3):241-249 (Pubitemid 41463777)
56. Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N (2006) rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun 343(1):190-197
57. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17(6):1053-1063
58. Drouet V, Perrin V, Hassig R et al (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65(3):276-285
59. Schmitt I, Linden M, Khazneh H, Evert BO, Breuer P, Klockgether T, Wuellner U (2007) Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 362(3):734-739 (Pubitemid 47368155)
60. Switonski PM, Fiszer A, Kazmierska K, Kurpisz M, Krzyzosiak WJ, Figiel M (2011) Mouse ataxin-3 functional knock-out model. Neuromolecular Med 13(1):54-65
61. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, Landwehrmeyer B, Vonsattel J-P, Zamore PD, Aronin N (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19 (9):774-778
62. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL, Paulson HL (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 100(12):7195-7200 (Pubitemid 36706415)
63. Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, Pedroso de Lima MC, Hantraye P, Pereira de Almeida L, Déglon N (2008) Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 3(10):e3341
64. Fiszer A, Mykowska A, Krzyzosiak WJ (2011) Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res 39(13):5578-85
65. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27(5): 478-484
66. Hu J, Liu J, Corey DR (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 17(11):1183-1188
67. Wojciechowska M, Krzyzosiak WJ (2011) Cellular toxicity of expanded RNA repeats: focus on RNA foci. Hum Mol Genet 20 (19):3811-3821
68. Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A, Kozlowski P (2012) Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res 40(1):11-26
69. Rangasamy SB, Soderstrom K, Bakay RAE, Kordower JH (2010) Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res 184:237-264
70. Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10(3):209-219
71. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, López-Barneo J (2008) Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11 (7):755-761 (Pubitemid 351896676)
72. Choi J-S, Kim SY, Park H-J, Cha J-H, Choi Y-S, Chung J-W, Chun M-H, Lee M-Y (2004) Differential regulation of ciliary neurotrophic factor and its receptor in the rat hippocampus in response to kainic acid-induced excitotoxicity. Mol Cells 17(2):292-296 (Pubitemid 39137079)
73. Royo NC, Conte V, Saatman KE, Shimizu S, Belfield CM, Soltesz KM, Davis JE, Fujimoto ST, McIntosh TK (2006) Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin-4/5 in pyramidal cell neuroprotection. Eur J Neurosci 23(5):1089-1102
74. Ramaswamy S, Soderstrom KE, Kordower JH (2009) Trophic factors therapy in Parkinson's disease. Prog Brain Res 175:201-216
75. Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5(6):311-322
76. Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293(5529):493-498 (Pubitemid 32679077)
77. Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, Valenza M, Cattaneo E (2005) Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res 52(2):133-139 (Pubitemid 40828363)
78. Gauthier LR, Charrin BC, Borrell-Pagès M et al (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118(1):127-138 (Pubitemid 38902819)
79. Zuccato C, Tartari M, Crotti A et al (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSEcontrolled neuronal genes. Nat Genet 35(1):76-83 (Pubitemid 37048599)
80. Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín- Ibañez R, Muñoz MT, Mengod G, Ernfors P, Alberch J (2004) Brainderived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 24(35):7727-7739 (Pubitemid 39186828)
81. Pineda JR, Canals JM, Bosch M, Adell A, Mengod G, Artigas F, Ernfors P, Alberch J (2005) Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease. J Neurochem 93(5):1057-1068 (Pubitemid 40776562)
82. Giralt A, Rodrigo T, Martín ED, Gonzalez JR, Milà M, Ceña V, Dierssen M, Canals JM, Alberch J (2009) Brain-derived neurotrophic factormodulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience 158(4):1234-1250
83. Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J (1999) Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther 10(18):2987-2997
84. de Almeida LP, Zala D, Aebischer P, Déglon N (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8(3):433-446 (Pubitemid 32566134)
85. Pérez-Navarro E, Canudas AM, Akerund P, Alberch J, Arenas E (2000) Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J Neurochem 75(5):2190-2199
86. Gharami K, Xie Y, An JJ, Tonegawa S, Xu B (2008) Brainderived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem 105(2):369-379 (Pubitemid 351490006)
87. Xie Y, Hayden MR, Xu B (2010) BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 30(44):14708-14718
88. Cho S-R, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA (2007) Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 117(10):2889-2902 (Pubitemid 47529619)
89. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, Zhou L, Pitzer MR, Berry-Kravis EM, Kordower JH (2006) Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 103(24):9345-9350 (Pubitemid 43902579)
90. Ramaswamy S, McBride JL, Han I, Berry-Kravis EM, Zhou L, Herzog CD, Gasmi M, Bartus RT, Kordower JH (2009) Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis 34(1):40-50
91. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL (2010) Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 214(2):193-200
92. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D, Logvinova A, Ross CA, Greenberg DA, Ellerby LM (2005) FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 102(50):18189-18194 (Pubitemid 41798523)
93. Zala D, Bensadoun J-C, Pereira de Almeida L, Leavitt BR, Gutekunst C-A, Aebischer P, Hayden MR, Déglon N (2004) Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Exp Neurol 185(1):26-35 (Pubitemid 38010276)
94. Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ (2008) Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice. J Neurosci Res 86(8):1748-1757 (Pubitemid 351859425)
95. DuanW, Guo Z, Jiang H, Ladenheim B, Xu X, Cadet JL, Mattson MP (2004) Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 55(4):590-594 (Pubitemid 38391979)
96. Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, Zhao M, Cadet JL,Wong J, Ross CA (2008) Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol Dis 30(3):312-322
97. Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, Hannan AJ (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 22(8):2081-2088 (Pubitemid 41579396)
98. Cheng Y, Peng Q, Hou Z, AggarwalM, Zhang J, Mori S, Ross CA, Duan W (2011) Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. NeuroImage 56(3):1027-1034
99. Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, Duan W (2008) The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 210(1):154-163
100. Martinowich K, Lu B (2008) Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33(1):73-83 (Pubitemid 350191318)
101. Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch G (2009) Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci U S A 106(12):4906-4911
102. Simmons DA, Mehta RA, Lauterborn JC, Gall CM, Lynch G (2011) Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol Dis 41(2):436-444
103. Apostol BL, Simmons DA, Zuccato C et al (2008) CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 39(1):8-20
104. DeMarch Z, Giampà C, Patassini S, Bernardi G, Fusco FR (2008) Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 30(3):375-387
105. Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR (2010) Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 5(10):e13417
106. Cho KJ, Lee BI, Cheon SY, Kim HW, Kim HJ, Kim GW (2009) Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease. Neuroscience 163(4):1128-1134
107. Saydoff JA, Garcia RAG, Browne SE et al (2006) Oral uridine prodrug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol Dis 24(3):455-465 (Pubitemid 44716675)
108. Hathorn T, Snyder-Keller A, Messer A (2011) Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease. Neurobiol Dis 41(1):43-50
109. Chiang M-C, Chen C-M, Lee M-R et al (2010) Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma. Hum Mol Genet 19(20):4043-4058
110. Borrell-Pagès M, Canals JM, Cordelières FP et al (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116(5):1410-1424
111. Duan W, Guo Z, Jiang H, Ware M, Li X-J, Mattson MP (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A 100(5):2911-2916 (Pubitemid 36297597)
112. Fumagalli E, Bigini P, Barbera S, De Paola M, Mennini T (2006) Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Exp Neurol 198(1):114-128 (Pubitemid 43243750)
113. Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, Riederer P, ter Meulen V, Koutsilieri E (2008) Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 33(9):2228-2236 (Pubitemid 351992085)
114. Greer PL, Greenberg ME (2008) From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 59(6):846-860
115. Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 81(5-6):294-330 (Pubitemid 46528643)
116. van Praag H, Kempermann G, Gage FH (2000) Neural consequences of environmental enrichment. Nat Rev Neurosci 1(3):191-198
117. van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ (2000) Delaying the onset of Huntington's in mice. Nature 404 (6779):721-722 (Pubitemid 30212388)
118. Carter RJ, Hunt MJ, Morton AJ (2000) Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov Disord 15(5):925-937
119. Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP (2002) Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 51(2):235-242 (Pubitemid 34111446)
120. Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RLM (2004) Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 123(1):207-212 (Pubitemid 37518488)
121. Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ (2004) Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 24(9):2270-2276 (Pubitemid 38314558)
122. Lazic SE, Grote HE, Blakemore C, Hannan AJ, van Dellen A, Phillips W, Barker RA (2006) Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci 23(7):1829-1838
123. Pang TYC, Stam NC, Nithianantharajah J, Howard ML, Hannan AJ (2006) Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience 141 (2):569-584 (Pubitemid 44066652)
124. Nithianantharajah J, Barkus C, Murphy M, Hannan AJ (2008) Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis 29(3):490-504
125. van Dellen A, Cordery PM, Spires TL, Blakemore C, Hannan AJ (2008) Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neurosci 9:34
126. Benn CL, Luthi-Carter R, Kuhn A et al (2010) Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 69(8):817-827
127. Wood NI, Glynn D, Morton AJ (2011) "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease. Neurobiol Dis 42(3):427-437
128. Zajac MS, Pang TYC, Wong N, Weinrich B, Leang LSK, Craig JM, Saffery R, Hannan AJ (2010) Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus 20(5):621-636
129. Wood NI, Carta V, Milde S et al (2010) Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease. PLoS One 5(2):e9077
130. Neeper SA, Gómez-Pinilla F, Choi J, Cotman CW (1996) Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res 726(1-2):49-56 (Pubitemid 26292229)
131. Rampon C, Jiang CH, Dong H, Tang YP, Lockhart DJ, Schultz PG, Tsien JZ, Hu Y (2000) Effects of environmental enrichment on gene expression in the brain. Proc Natl Acad Sci USA 97 (23):12880-12884
132. Brown J, Cooper-Kuhn CM, Kempermann G, Van Praag H, Winkler J, Gage FH, Kuhn HG (2003) Enriched environment and physical activity stimulate hippocampal but not olfactory bulb neurogenesis. Eur J Neurosci 17(10):2042-2046 (Pubitemid 36713965)
133. Kohl Z, Kandasamy M, Winner B, Aigner R, Gross C, Couillard-Despres S, Bogdahn U, Aigner L,Winkler J (2007) Physical activity fails to rescue hippocampal neurogenesis deficits in the R6/2 mouse model of Huntington's disease. Brain Res 1155:24-33 (Pubitemid 46891433)
134. Schwarcz R, Guidetti P, Sathyasaikumar KV,Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 90(2):230-245
135. Figueredo-Cardenas G, Harris CL, Anderson KD, Reiner A (1998) Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp Neurol 149(2):356-372 (Pubitemid 28115074)
136. Foster AC, Collins JF, Schwarcz R (1983) On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 22 (12A):1331-1342 (Pubitemid 14222225)
137. Graham RK, Pouladi MA, Joshi P et al (2009) Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29(7):2193-2204
138. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33(6):849-860 (Pubitemid 34246352)
139. Levine MS, Klapstein GJ, Koppel A et al (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knock-in mouse models
140. Cummings DM, Cepeda C, Levine MS (2010) Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro 2(3):e00036
141. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86(6):2667-2677 (Pubitemid 33139038)
142. Starling AJ, André VM, Cepeda C, de Lima M, Chandler SH, Levine MS (2005) Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res 82(3):377-386 (Pubitemid 41552488)
143. André VM, Cepeda C, Venegas A, Gomez Y, Levine MS (2006) Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease. J Neurophysiol 95 (4):2108-2119
144. Cummings DM, André VM, Uzgil BO, Gee SM, Fisher YE, Cepeda C, Levine MS (2009) Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 29(33):10371-10386
145. Cepeda C,Wu N, André VM, Cummings DM, Levine MS (2007) The corticostriatal pathway in Huntington's disease. Prog Neurobiol 81(5-6):253-271 (Pubitemid 46528639)
146. Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R (2006) Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis 23(1):190-197 (Pubitemid 43922462)
147. Fan MMY, Raymond LA (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 81(5-6):272-293 (Pubitemid 46528641)
148. Léveillé F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A (2008) Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J 22(12):4258-4271
149. Okamoto S, Pouladi MA, Talantova M et al (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15(12):1407-1413
150. Milnerwood AJ, Gladding CM, Pouladi MA et al (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65(2):178-190
151. Stanika RI, Pivovarova NB, Brantner CA, Watts CA, Winters CA, Andrews SB (2009) Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci U S A 106(24):9854-9859
152. Tallaksen-Greene SJ, Janiszewska A, Benton K, Ruprecht L, Albin RL (2010) Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp Neurol 225(2):402-407
153. Schilling G, Coonfield ML, Ross CA, Borchelt DR (2001) Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 315(3):149-153 (Pubitemid 33079072)
154. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22 (5):1592-1599 (Pubitemid 35386278)
155. Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F (2004) Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis 17(1):77-88 (Pubitemid 39209315)
156. Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P (2007) Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol Dis 28(2):197-205 (Pubitemid 47615458)
157. Chiang M-C, Chen H-M, Lai H-L, Chen H-W, Chou S-Y, Chen C-M, Tsai F-J, Chern Y (2009) The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Hum Mol Genet 18(16):2929-2942
158. Huang N-K, Lin J-H, Lin J-T et al (2011) A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One 6(6):e20934
159. Chou S-Y, Lee Y-C, Chen H-M et al (2005) CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 93(2):310-320 (Pubitemid 40547488)
160. Schiefer J, Sprünken A, Puls C, Lüesse H-G, Milkereit A, Milkereit E, Johann V, Kosinski CM (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 1019(1-2):246-254 (Pubitemid 39078630)
161. Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP (2012) The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice. Neurobiol Dis 47(1):75-91
162. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153(1):329-337
163. Sari Y, Prieto AL, Barton SJ, Miller BR, Rebec GV (2010) Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease. J Biomed Sci 17:62
164. Figiel M, Engele J (2000) Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuron-derived peptide regulating glial glutamate transport and metabolism. J Neurosci 20(10):3596-3605 (Pubitemid 30266222)
165. Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J (2003) Regulation of glial glutamate transporter expression by growth factors. Exp Neurol 183(1):124-135 (Pubitemid 37075863)
166. Tang T-S, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 27(30):7899-7910 (Pubitemid 47173323)
167. Wang H, Chen X, Li Y, Tang T-S, Bezprozvanny I (2010) Tetrabenazine is neuroprotective in Huntington's disease mice. Mol Neurodegener 5:18
168. Masuda N, Peng Q, Li Q, Jiang M, Liang Y, Wang X, Zhao M, Wang W, Ross CA, Duan W (2008) Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis 30(3):293-302
169. Dowie MJ, Howard ML, Nicholson LFB, Faull RLM, Hannan AJ, Glass M (2010) Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience 170(1):324-336
170. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F (2010) Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets 9(6):791-800
171. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17(3):455-461 (Pubitemid 39574879)
172. Sathyasaikumar KV, Stachowski EK, Amori L, Guidetti P, Muchowski PJ, Schwarcz R (2010) Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem 113(6):1416-1425
173. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, Giorgini F (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 21(11):961-966
174. Zwilling D, Huang S-Y, Sathyasaikumar KV et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145(6):863-874
175. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39(3):385-389 (Pubitemid 26100764)
176. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41(5):646-653 (Pubitemid 27212659)
177. Panov A, Obertone T, Bennett-Desmelik J, Greenamyre JT (1999) Ca(2+)-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington's or Alzheimer's disease. Ann N Y Acad Sci 893:365-368 (Pubitemid 30038106)
178. Panov AV, Gutekunst C-A, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5(8):731-736 (Pubitemid 34827590)
179. Milakovic T, Johnson GVW (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280(35):30773-30782 (Pubitemid 41291807)
180. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127(1):59-69 (Pubitemid 44466642)
181. Weydt P, Pineda VV, Torrence AE et al (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4(5):349-362 (Pubitemid 44645069)
182. Lemasters JJ, Theruvath TP, Zhong Z, Nieminen A-L (2009) Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta 1787(11):1395-1401
183. Choo YS, Johnson GVW, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13(14):1407-1420 (Pubitemid 39023049)
184. Block-Galarza J, Chase KO, Sapp E, Vaughn KT, Vallee RB, DiFiglia M, Aronin N (1997) Fast transport and retrograde movement of huntingtin and HAP 1 in axons. Neuroreport 8(9-10):2247-2251 (Pubitemid 27319681)
185. Orr AL, Li S, Wang C-E, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li X-J (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28(11):2783-2792 (Pubitemid 351398886)
186. Chang DTW, Rintoul GL, Pandipati S, Reynolds IJ (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22(2):388-400
187. Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ (2006) Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 1762(6):616-626 (Pubitemid 43903119)
188. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ (2006) Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 1762(3):373-380 (Pubitemid 43172854)
189. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects inmodels of Parkinson's and Huntington's diseases. J Neurochem 109(5):1427-1439
190. Menalled LB, Patry M, Ragland N et al (2010) Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 5(3):e9793
191. Bhagavan HN, Chopra RK (2006) Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 40(5):445-453
192. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ (2010) Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 19 (4):535-554
193. AndreassenOA, Ferrante RJ,HuangHMet al (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 50(1):112-117
194. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF (2001) Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12(15):3371-3373 (Pubitemid 33010674)
195. Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 85(6):1359-1367 (Pubitemid 36702548)
196. Andreassen OA, Dedeoglu A, Ferrante RJ et al (2001) Creatine increase survival and delaysmotor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8(3):479-491 (Pubitemid 32566138)
197. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20 (12):4389-4397 (Pubitemid 30396603)
198. Ruskin DN, Ross JL, KawamuraMJr, Ruiz TL, Geiger JD,Masino SA (2011) A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1 J mouse model of Huntington's disease. Physiol Behav 103(5):501-507
199. Emerit J, Edeas M, Bricaire F (2004) Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 58(1):39-46 (Pubitemid 38117047)
200. Lee J, Kosaras B, Del Signore SJ, Cormier K, McKee A, Ratan RR, Kowall NW, Ryu H (2011) Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathol 121(4):487-498
201. Keene CD, Rodrigues CMP, Eich T, Chhabra MS, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A 99(16):10671-10676
202. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier P-E, Beal MF (2003) Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem 86(1):267-272 (Pubitemid 36753867)
203. Rebec GV, Barton SJ, Marseilles AM, Collins K (2003) Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14(9):1263-1265 (Pubitemid 36928600)
204. Vamos E, Voros K, Vecsei L, Klivenyi P (2010) Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomed Pharmacother 64(4):282-286
205. Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF (2010) Triterpenoids CDDOethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med 49(2):147-158
206. Ellrichmann G, Petrasch-Parwez E, Lee D-H, Reick C, Arning L, Saft C, Gold R, Linker RA (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 6(1):e16172
207. Chaturvedi RK, Adhihetty P, Shukla S et al (2009) Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet 18(16):3048-3065
208. Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol 225(1):74-84
209. JeongH, CohenDE, Cui L, SupinskiA, Savas JN,Mazzulli JR,Yates JR 3rd, Bordone L, Guarente L, Krainc D (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18(1):159-165
210. Jiang M, Wang J, Fu J et al (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 18(1):153-158
211. Wang H, Guan Y, Wang X et al (2007) Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur J Neurosci 26(3):633-641 (Pubitemid 47206781)
212. Perry GM, Tallaksen-Greene S, Kumar A, Heng MY, Kneynsberg A, van Groen T, Detloff PJ, Albin RL, Lesort M (2010) Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease. Hum Mol Genet 19(17):3354-3371
213. Sánchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 22(3):623-633 (Pubitemid 29159860)
214. Chen M, Ona VO, Li M et al (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6 (7):797-801 (Pubitemid 30469429)
215. Gervais FG, Singaraja R, Xanthoudakis S et al (2002) Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol 4(2):95-105 (Pubitemid 34141474)
216. Hermel E, Gafni J, Propp SS et al (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 11(4):424-438 (Pubitemid 38489420)
217. Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ (2002) Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Med 1(3):183-195 (Pubitemid 37012515)
218. Zhang H, Li Q, Graham RK, Slow E, HaydenMR, Bezprozvanny I (2008) Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis 31(1):80-88
219. Chou A-H, Yeh T-H, Kuo Y-L, Kao Y-C, JouM-J, Hsu C-Y, Tsai SR, Kakizuka A,Wang H-L (2006) Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiol Dis 21(2):333-345 (Pubitemid 43099857)
220. Wang H-L, Yeh T-H, Chou A-H, Kuo Y-L, Luo L-J, He C-Y, Huang P-C, Li AH (2006) Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-x(L). Cell Signal 18 (4):541-552 (Pubitemid 41790374)
221. Chou A-H, Lin A-C, Hong K-Y, Hu S-H, Chen Y-L, Chen J-Y, Wang H-L (2011) p53 activation mediates polyglutamineexpanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons. Neurochem Int 58(2):145-152
222. Young JE, Garden GA, Martinez RA et al (2009) Polyglutamineexpanded androgen receptor truncation fragments activate a Baxdependent apoptotic cascade mediated by DP5/Hrk. J Neurosci 29(7):1987-1997
223. Wellington CL, Ellerby LM, Gutekunst C-A et al (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci 22(18):7862-7872 (Pubitemid 35379091)
224. Berke SJS, Schmied FAF, Brunt ER, Ellerby LM, Paulson HL (2004) Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 89(4):908-918 (Pubitemid 38684738)
225. Young JE, Gouw L, Propp S et al (2007) Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol Chem 282(41):30150-30160 (Pubitemid 350035251)
226. Ellerby LM, Hackam AS, Propp SS et al (1999) Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem 72(1):185-195 (Pubitemid 29013892)
227. Ellerby LM, Andrusiak RL, Wellington CL et al (1999) Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 274(13):8730-8736 (Pubitemid 29164670)
228. Graham RK, Deng Y, Slow EJ et al (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125(6):1179-1191 (Pubitemid 43866195)
229. Tebbenkamp ATN, Green C, Xu G et al (2011) Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative. Hum Mol Genet 20(14):2770-2782
230. Waldron-Roby E, Ratovitski T, Wang X et al (2012) Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. J Neurosci 32(1):183-193
231. Nagley P, Higgins GC, Atkin JD, Beart PM (2010) Multifaceted deaths orchestrated by mitochondria in neurones. Biochim Biophys Acta 1802(1):167-185
232. Ona VO, Li M, Vonsattel JP et al (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399(6733):263-267 (Pubitemid 29246456)
233. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 100(18):10483-10487 (Pubitemid 37071904)
234. Diguet E, Fernagut P-O, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F (2004) Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19(12):3266-3276 (Pubitemid 38859544)
235. Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, Ledent C, Blum D (2007) Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromolecular Med 9(1):47-54 (Pubitemid 44772275)
236. Hersch S, Fink K, Vonsattel JP, Friedlander RM (2003) Minocycline is protective in a mouse model of Huntington's disease. Ann Neurol 54(6):841, author reply 842-843
237. Bonelli RM, Hödl AK, Hofmann P, Kapfhammer H-P (2004) Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19(6):337-342 (Pubitemid 39506988)
238. Thomas M, Ashizawa T, Jankovic J (2004) Minocycline in Huntington's disease: a pilot study. Mov Disord 19(6):692-695 (Pubitemid 39173025)
239. Huntington Study Group (2004) Minocycline safety and tolerability in Huntington disease. Neurology 63(3):547-549
240. Plane JM, Shen Y, Pleasure DE, Deng W (2010) Prospects for minocycline neuroprotection. Arch Neurol 67(12):1442-1448
241. Gordon PH, Moore DH, Miller RG et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6(12):1045-1053 (Pubitemid 350116691)
242. Huntington Study Group DOMINO Investigators (2010) A futility study of minocycline in Huntington's disease. Mov Disord 25 (13):2219-2224
243. Wang X, Zhu S, Pei Z et al (2008) Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci 28(38):9473-9485
244. Díaz-Hernández M, Díez-Zaera M, Sánchez- Nogueiro J, Gómez-Villafuertes R, Canals JM, Alberch J, Miras-Portugal MT, Lucas JJ (2009) Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J 23(6):1893-1906
245. Arzberger T, Krampfl K, Leimgruber S, Weindl A (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J Neuropathol Exp Neurol 56(4):440-454 (Pubitemid 27465027)
246. Augood SJ, Faull RL, Love DR, Emson PC (1996) Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72(4):1023-1036 (Pubitemid 26135583)
247. Evert BO, Vogt IR, Vieira-Saecker AM, Ozimek L, de Vos RAI, Brunt ERP, Klockgether T, Wüllner U (2003) Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol 62 (10):1006-1018 (Pubitemid 37229531)
248. Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 3(2):157-163 (Pubitemid 30126331)
249. Luthi-Carter R, Strand AD, Hanson SA et al (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 11 (17):1927-1937 (Pubitemid 34919269)
250. Helmlinger D, Hardy S, Sasorith S et al (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 13(12):1257-1265 (Pubitemid 38877879)
251. Tsai C-C, Kao H-Y, Mitzutani A, Banayo E, Rajan H, McKeown M, Evans RM (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci USA 101(12):4047-4052 (Pubitemid 38405881)
252. Mizutani A, Wang L, Rajan H, Vig PJS, Alaynick WA, Thaler JP, Tsai C-C (2005) Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J 24(18):3339-3351 (Pubitemid 41348707)
253. Tong X, Gui H, Jin F, Heck BW, Lin P, Ma J, Fondell JD, Tsai CC (2011) Ataxin-1 and Brother of ataxin-1 are components of the Notch signalling pathway. EMBO Rep 12(5):428-435
254. Li F, Macfarlan T, Pittman RN, Chakravarti D (2002) Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 277(47):45004-45012 (Pubitemid 36159099)
255. Evert BO, Araujo J, Vieira-Saecker AM, de Vos RAI, Harendza S, Klockgether T, Wüllner U (2006) Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci 26(44):11474-11486 (Pubitemid 44772178)
256. Shimohata T, Nakajima T, Yamada M et al (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26(1):29-36
257. Okazawa H, Rich T, Chang A et al (2002) Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34(5):701-713 (Pubitemid 34628734)
258. Bae B-I, Xu H, Igarashi S et al (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47(1):29-41 (Pubitemid 40922848)
259. Li S-H, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li X-J (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol 22(5):1277-1287 (Pubitemid 34150765)
260. Arango M, Holbert S, Zala D et al (2006) CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J Neurosci 26 (17):4649-4659 (Pubitemid 44315366)
261. Desplats PA, Lambert JR, Thomas EA (2008) Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. Neurobiol Dis 31(3):298-308
262. Butler R, Bates GP (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7(10):784-796 (Pubitemid 44435261)
263. McCampbell A, Taylor JP, Taye AA et al (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet 9(14):2197-2202
264. Nucifora FC Jr, Sasaki M, Peters MF et al (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291(5512):2423-2428 (Pubitemid 32231807)
265. Jiang H, Nucifora FC Jr, Ross CA, DeFranco DB (2003) Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 12(1):1-12 (Pubitemid 36097710)
266. Stenoien DL, Mielke M, Mancini MA (2002) Intranuclear ataxin1 inclusions contain both fast-and slow-exchanging components. Nat Cell Biol 4(10):806-810 (Pubitemid 35214775)
267. Sadri-Vakili G, Bouzou B, Benn CL et al (2007) Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 16(11):1293-1306 (Pubitemid 47055125)
268. Giampà C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D, Bernardi G, Ammassari-Teule M, Fusco FR (2009) Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur J Neurosci 29(5):902-910
269. Chou A-H, Chen S-Y, Yeh T-H, Weng Y-H, Wang H-L (2011) HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 41(2):481-488
270. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Sobue G (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13(11):1183-1192 (Pubitemid 38787000)
271. Ying M, Xu R, Wu X, Zhu H, Zhuang Y, Han M, Xu T (2006) Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J Biol Chem 281(18):12580-12586 (Pubitemid 43855346)
272. Gardian G, Browne SE, Choi D-K et al (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280(1):556-563 (Pubitemid 40165021)
273. Zádori D, Geisz A, Vámos E, Vécsei L, Klivényi P (2009) Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 94(1):148-153
274. Ferrante RJ, Kubilus JK, Lee J et al (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23(28):9418-9427 (Pubitemid 37323042)
275. Hockly E, Richon VM, Woodman B et al (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100(4):2041-2046 (Pubitemid 36254570)
276. Thomas EA, Coppola G, Desplats PA et al (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 105(40):15564-15569
277. Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A 103(50):19176-19181 (Pubitemid 350002846)
278. Ferrante RJ, Ryu H, Kubilus JK et al (2004) Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mousemodel of Huntington's disease. J Neurosci 24(46):10335-10342 (Pubitemid 39552617)
279. Stack EC, Del Signore SJ, Luthi-Carter R et al (2007) Modulation of nucleosome dynamics in Huntington's disease. Hum Mol Genet 16(10):1164-1175 (Pubitemid 47062713)
280. Manji HK, Moore GJ, Chen G (2000) Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61(Suppl 9):82-96
281. Chen G, Masana MI, Manji HK (2000) Lithium regulates PKCmediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2(3 Pt 2):217-236
282. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278(35):33067-33077 (Pubitemid 37055753)
283. Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, Mizusawa H, Orr HT, Shaw C, Zoghbi HY (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 4(5):e182
284. Wood NI, Morton AJ (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 61(4):375-383 (Pubitemid 36945468)
285. Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A (2003) DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 7(5 Pt 1):572-579 (Pubitemid 36626236)
286. Bowman AB, Lam YC, Jafar-Nejad P, Chen H-K, Richman R, Samaco RC, Fryer JD, Kahle JJ, Orr HT, Zoghbi HY (2007) Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet 39(3):373-379 (Pubitemid 46328494)
287. Norflus F, Nanje A, Gutekunst C-A, Shi G, Cohen J, Bejarano M, Fox J, Ferrante RJ, Hersch SM (2004) Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis 17(2):319-325 (Pubitemid 39345787)
288. Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK (2002) Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 11(3):410-424 (Pubitemid 36269126)
289. Josefsen K, Nielsen MD, Jørgensen KH, Bock T, Nø rremølle A, Sørensen SA, Naver B, Hasholt L (2008) Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease. J Neuroendocrinol 20(2):165-172 (Pubitemid 351147003)
290. Strand AD, Aragaki AK, Shaw D et al (2005) Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 14(13):1863-1876 (Pubitemid 41418057)
291. Hunt MJ, Morton AJ (2005) Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 166(2):220-229 (Pubitemid 41406813)
292. Henriksen EJ (2002) Invited review: Effects of acute exercise and exercise training on insulin resistance. J Appl Physiol 93(2):788-796 (Pubitemid 34810247)
293. Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR (2007) Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett 411(2):98-103 (Pubitemid 44822618)
294. Martin B, Golden E, Carlson OD et al (2009) Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58(2):318-328
295. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8(2):143-149 (Pubitemid 34155125)
296. Dedeoglu A, Kubilus JK, Jeitner TM et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22(20):8942-8950 (Pubitemid 35379064)
297. Wang X, Sarkar A, Cicchetti F, Yu M, Zhu A, Jokivarsi K, Saint-Pierre M, Brownell A-L (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 231(1-2):57-66 (Pubitemid 40439235)
298. Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR (2005) Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 95(1):210-220 (Pubitemid 41384439)
299. Mastroberardino PG, Iannicola C, Nardacci R et al (2002) "Tissue" transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9(9):873-880 (Pubitemid 35023603)
300. McConoughey SJ, BassoM,Niatsetskaya ZVet al (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2(9):349-370
301. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci 25(1):157-163 (Pubitemid 40110776)
302. Pedroso JL, Braga-Neto P, Felício AC, Dutra LA, Santos WAC, do Prado GF, Barsottini OGP (2011) Sleep disorders in machadojoseph disease: frequency, discriminative thresholds, predictive values, and correlation with ataxia-related motor and non-motor features. Cerebellum 10(2):291-295
303. Hara J, Beuckmann CT, Nambu T et al (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30(2):345-354 (Pubitemid 32530580)
304. Pallier PN, Morton AJ (2009) Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease. Brain Res 1279:90-98
305. Pallier PN, Maywood ES, Zheng Z, Chesham JE, Inyushkin AN, Dyball R, Hastings MH, Morton AJ (2007) Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J Neurosci 27(29):7869-7878 (Pubitemid 47093825)
306. Van Raamsdonk JM, Murphy Z, Selva DM et al (2007) Testicular degeneration in Huntington disease. Neurobiol Dis 26(3):512-520 (Pubitemid 46756321)
307. KatsunoM, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35(5):843-854
308. Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9(6):768-773 (Pubitemid 36749228)
309. Chevalier-Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L, Lieberman AP, Merry DE (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24(20):4778-4786 (Pubitemid 38668202)
310. Hult S, Schultz K, Soylu R, Petersén A (2010) Hypothalamic and neuroendocrine changes in Huntington's disease. Curr Drug Targets 11(10):1237-1249
311. Mangiarini L, Sathasivam K, Seller M et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (3):493-506 (Pubitemid 26374323)
312. Schilling G, Becher MW, Sharp AH et al (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8(3):397-407 (Pubitemid 29097327)
313. Landles C, Sathasivam K, Weiss A et al (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285(12):8808-8823
314. Hodgson JG, Agopyan N, Gutekunst CA et al (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23(1):181-192 (Pubitemid 29262475)
315. Slow EJ, van Raamsdonk J, Rogers D et al (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12(13):1555-1567 (Pubitemid 36857303)
316. Brooks S, Higgs G, Janghra N, Jones L, Dunnett SB (2012) Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6 J) Huntington's disease transgenic mice. Brain Res Bull 88(2-3):113-120
317. Ferrante RJ (2009) Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 1792(6):506-520
318. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet M-F (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465(1):11-26 (Pubitemid 37075677)
319. Wheeler VC, White JK, Gutekunst CA et al (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9(4):503-513 (Pubitemid 30154008)
320. Gray M, Shirasaki DI, Cepeda C et al (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28(24):6182-6195
321. Kotliarova S, Jana NR, Sakamoto N et al (2005) Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J Neurochem 93(3):641-653 (Pubitemid 40617624)
322. Hoppitt T, Pall H, Calvert M, Gill P, Yao G, Ramsay J, James G, Conduit J, Sackley C (2011) A systematic review of the incidence and prevalence of long-term neurological conditions in the UK. Neuroepidemiology 36(1):19-28
323. Klockgether T (2008) The clinical diagnosis of autosomal dominant spinocerebellar ataxias. Cerebellum 7(2):101-105
324. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82(6):937-948
325. Watase K, Weeber EJ, Xu B et al (2002) A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34(6):905-919 (Pubitemid 34722281)
326. Yoo SY, Pennesi ME, Weeber EJ, Xu B, Atkinson R, Chen S, Armstrong DL, Wu SM, Sweatt JD, Zoghbi HY (2003) SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37(3):383-401 (Pubitemid 36183362)
327. Sato T, Miura M, Yamada M et al (2009) Severe neurological phenotypes of Q129 DRPLA transgenic mice serendipitously created by en masse expansion of CAG repeats in Q76 DRPLA mice. Hum Mol Genet 18(4):723-736
328. Willner P (1986) Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 10(6):677-690 (Pubitemid 17185919)
329. Willner P (1991) Methods for assessing the validity of animals models of human psychopathology. Animal models in psychiatry. The Humana Press Inc., Clifton, pp 1-24
330. Heng MY, Detloff PJ, Albin RL (2008) Rodent genetic models of Huntington disease. Neurobiol Dis 32(1):1-9
331. Dorsey R, Shoulson I (2011) Huntington's disease, clinical experimental therapeutics. Neurobiology of Huntington's disease: applications to drug discovery. CRC Press, Boca Raton
332. Dunnett SB, Carter RJ, Watts C, Torres EM, Mahal A, Mangiarini L, BatesG,Morton AJ (1998) Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp Neurol 154(1):31-40 (Pubitemid 28553564)
333. Deckel AW, Volmer P, Weiner R, Gary KA, Covault J, Sasso D, Schmerler N, Watts D, Yan Z, Abeles I (2000) Dietary arginine alters time of symptom onset in Huntington's disease transgenic mice. Brain Res 875(1-2):187-195
334. Deckel AW, Tang V, Nuttal D, Gary K, Elder R (2002) Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice. Brain Res 939(1-2):76-86 (Pubitemid 34518591)
335. van Dellen A, Deacon R, York D, Blakemore C, Hannan AJ (2001) Anterior cingulate cortical transplantation in transgenic Huntington's disease mice. Brain Res Bull 56(3-4):313-318 (Pubitemid 33062355)
336. Clifford JJ,Drago J, Natoli AL,Wong JYF, KinsellaA,Waddington JL, Vaddadi KS (2002) Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 109(1):81-88 (Pubitemid 34088148)
337. Schiefer J, Landwehrmeyer GB, Lüesse H-G, Sprünken A, Puls C, Milkereit A, Milkereit E, Kosinski CM (2002) Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord 17(4):748-757 (Pubitemid 41295019)
338. Gil JMAC, Leist M, Popovic N, Brundin P, Petersén A (2004) Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci 5:17
339. Zucker B, Ludin DE, Gerds TA, Lücking CH, Landwehrmeyer GB, Feuerstein TJ (2004) Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease. Naunyn Schmiedebergs Arch Pharmacol 370(2):131-139 (Pubitemid 39222865)
340. Morton AJ, HuntMJ, Hodges AK, Lewis PD, Redfern AJ, Dunnett SB, Jones L (2005)A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur J Neurosci 21(4):855-870 (Pubitemid 40461039)
341. Nguyen T, Hamby A, Massa SM (2005) Clioquinol downregulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 102(33):11840-11845 (Pubitemid 41170812)
342. Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR (2005) Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 196(2):266-272 (Pubitemid 41607814)
343. Bailey CDC, Johnson GVW (2006) The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 27(6):871-879 (Pubitemid 44287905)
344. Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP (2006) Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum Mol Genet 15(1):33-44 (Pubitemid 43020102)
345. Qiu Z, Norflus F, Singh B et al (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 281(24):16672-16680
346. Dey ND, Boersen AJ, Myers RA, York LR, Bombard MC, Lu M, Sandstrom MI, Hulce VD, Lescaudron L, Dunbar GL (2007) The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease. Restor Neurol Neurosci 25(5-6):485-492 (Pubitemid 351525711)
347. Glynn D, Reim K, Brose N, Morton AJ (2007) Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD. Brain Res Bull 72(2-3):108-120 (Pubitemid 46367456)
348. Merienne K, Friedman J, Akimoto M, Abou-Sleymane G, Weber C, Swaroop A, Trottier Y (2007) Preventing polyglutamineinduced activation of c-Jun delays neuronal dysfunction in a mouse model of SCA7 retinopathy. Neurobiol Dis 25(3):571-581 (Pubitemid 46321517)
349. Stack EC, Dedeoglu A, Smith KM et al (2007) Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J Neurosci 27(47):12908-12915 (Pubitemid 350159593)
350. Yang Z, Chang Y-J, Yu I-C et al (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 13(3):348-353 (Pubitemid 46376683)
351. Zourlidou A, Gidalevitz T, Kristiansen M et al (2007) Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet 16(9):1078-1090 (Pubitemid 47062728)
352. Cipriani S, Bizzoco E, Gianfriddo M, Melani A, Vannucchi MG, Pedata F (2008) Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Exp Neurol 213(1):163-170
353. Chen X, Tang T-S, Tu H, Nelson O, Pook M, Hammer R, Nukina N, Bezprozvanny I (2008) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J Neurosci 28 (48):12713-12724
354. Chintawar S, Hourez R, Ravella A, Gall D, Orduz D, Rai M, Bishop DP, Geuna S, Schiffmann SN, Pandolfo M (2009) Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model. J Neurosci 29(42):13126-13135
355. Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA (2009) Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease. J Neurosci 29(37):11550-11559
356. Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP (2009) Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS One 4(6):e5747
357. Lee S-T, Chu K, Jung K-H et al (2009) Slowed progression in models of Huntington disease by adipose stem cell transplantation. Ann Neurol 66(5):671-681
358. Li M, Huang Y, Ma AAK, Lin E, Diamond MI (2009) Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol Dis 36(3):413-420
359. Liu J, Tang T-S, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I (2009) Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci 29(29):9148-9162
360. Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63(3):316-328
361. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132 (Pt 4):919-932
362. Tallaksen-Greene SJ, Janiszewska A, Benton K, Hou G, Dick R, Brewer GJ, Albin RL (2009) Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease. Neurosci Lett 452(1):60-62
363. Tang T-S, Guo C, Wang H, Chen X, Bezprozvanny I (2009) Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J Neurosci 29(5):1257-1266
364. Vamos E, Voros K, Zadori D, Vecsei L, Klivenyi P (2009) Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. J Neural Transm 116(9):1079-1086
365. Bauer PO, Goswami A, Wong HK et al (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol 28(3):256-263
366. Decressac M, Wright B, Tyers P, Gaillard A, Barker RA (2010) Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp Neurol 226(1):24-32
367. Snyder BR, Chiu AM, Prockop DJ, Chan AWS (2010) Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS One 5(2):e9347
368. Chen X,Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I (2011) Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener 6:81
369. Duarte AI, Petit GH, Ranganathan S, Li J-Y, Oliveira CR, Brundin P, Björkqvist M, Rego AC (2011) IGF-1 protects against diabetic features in an in vivo model of Huntington's disease. Exp Neurol 231(2):314-319
370. Hourez R, Servais L, Orduz D, Gall D, Millard I, de Kerchove d'Exaerde A, Cheron G, Orr HT, Pandolfo M, Schiffmann SN (2011) Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 31(33):11795-11807
371. Jafar-Nejad P, Ward CS, Richman R, Orr HT, Zoghbi HY (2011) Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Natl Acad Sci U S A 108(5):2142-2147
372. Lim S, Chesser AS, Grima JC, Rappold PM, Blum D, Przedborski S, Tieu K (2011) D-β-hydroxybutyrate is protective in mouse models of Huntington's disease. PLoS One 6(9):e24620
373. Lin Y-S, Chen C-M, Soong B et al (2011) Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. J Clin Invest 121(4):1519-1523
374. Lin Y-T, Chern Y, Shen C-KJ, Wen H-L, Chang Y-C, Li H, Cheng T-H, Hsieh-Li HM (2011) Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS One 6(8):e22924
375. Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet 20(2):261-270
376. Mughal MR, Baharani A, Chigurupati S, Son TG, Chen E, Yang P, Okun E, Arumugam T, Chan SL, Mattson MP (2011) Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice. Hum Mol Genet 20(4):659-669
377. Bobrowska A, Paganetti P, Matthias P, Bates GP (2011) Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS One 6(6):e20696
378. Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, White MF (2011) IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 121(10):4070-4081
379. Chang Y-K, Chen M-H, Chiang Y-H, Chen Y-F, Ma W-H, Tseng C-Y, Soong B-W, Ho JH, Lee OK (2011) Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells. J Biomed Sci 18:54
380. Vig PJS, Hearst S, Shao Q, Lopez ME, Murphy HA 2nd, Safaya E (2011) Glial S100B protein modulates mutant Ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapy. Cerebellum 10(2):254-266
381. Wang X, Sirianni A, Pei Z et al (2011) The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 31(41):14496-14507
382. Zhu S, Zhang Y, Bai G, Li H (2011) Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease. Cell Death Dis 2:e115
383. Chang Y-C, Lin C-Y, Hsu C-M, Lin H-C, Chen Y-H, Lee-Chen G-J, Su M-T, Ro L-S, Chen C-M, Hsieh-Li HM (2011) Neuroprotective effects of granulocyte-colony stimulating factor in a novel transgenic mouse model of SCA17. J Neurochem 118 (2):288-303
384. Chen KA, Cruz PE, Lanuto DJ, Flotte TR, Borchelt DR, Srivastava A, Zhang J, Steindler DA, Zheng T (2011) Cellular fusion for gene delivery to SCA1 affected Purkinje neurons. Mol Cell Neurosci 47(1):61-70
385. Chen X, Wu J, Luo Y et al (2011) Expanded polyglutaminebinding peptoid as a novel therapeutic agent for treatment of Huntington's disease. Chem Biol 18(9):1113-1125
386. Di Pardo A, Maglione V, Alpaugh M et al (2012) Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci U S A 109(9):3528-3533
387. Kwan W, Magnusson A, Chou A et al (2012) Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci 32(1):133-142
388. Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP (2012) Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS One 7(2):e31080
389. Noma S, Ohya-Shimada W, Kanai M, Ueda K, Nakamura T, Funakoshi H (2012) Overexpression of HGF attenuates the degeneration of Purkinje cells and Bergmann glia in a knockin mouse model of spinocerebellar ataxia type 7. Neurosci Res 73(2):115-21
390. Kordasiewicz HB, Stanek LM, Wancewicz EV et al (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of Huntingtin synthesis. Neuron 74(6):1031-1044
391. Pouladi MA, Brillaud E, Xie Y et al (2012) NP03, a novel lowdose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis. doi:10.1016/j.nbd.2012.06.026
392. Helmlinger D, Bonnet J, Mandel J-L, Trottier Y, Devys D (2004) Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice. J Biol Chem 279(53):55969-55977 (Pubitemid 40066604)
393. Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP, Cheetham ME (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain: A Journal of Neurology 135(Pt 4):1180-96
394. Ebert AD, Barber AE, Heins BM, Svendsen CN (2010) Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 224(1):155-162
395. Popovic N, Maingay M, Kirik D, Brundin P (2005) Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 193(1):65-74 (Pubitemid 40463268)
396. Cvetanovic M, Patel JM, Marti HH, Kini AR, Opal P (2011) Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1. Nat Med 17(11):1445-1447
397. Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 6(11):e27746